NCT03852082Active, not recruiting
Predictors and Clinical Outcomes of Patients With Coronary Heart Disease Co-morbid Depression Post Percutaneous Coronary Intervention
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
A prospective, multicenter, registered cohort study to observe the incidence of 1-year major adverse cardiac events in patients with coronary heart disease co-morbid depression treated with percutaneous coronary intervention and to clarify the predictors of 1-year major adverse cardiac events post PCI among these patients.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 2600 (estimated)
- First submitted
- 21 Feb 2019
- Start date
- 28 Aug 2019
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- Nanjing First Hospital, Nanjing Medical University
- Diseases
- Coronary artery disease
- NCT number
- NCT03852082
What you commit to
- Study type: Observational
- Planned participants: 2600
- From 28 Aug 2019 to the primary completion date, 30 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosed mental illness or medical history (including schizophrenia, bipolar disorder, severe dementia or Lifetime alcohol or substance abuse);
Other
- Inability to provide written informed consent;
- Tendency of suicide;
- Pregnant or lactating women;
- Any physical or intellectual inability or disability that may affect completion of self-assessment tools, study protocol and follow-up requirements;
- Any other reasons that investigators based on professional judgments that would place the patient at increased risk.
- Patient with STEMI within 24-hour from the onset of chest pain to admission.
Who the study is looking for
- Provision of informed consent prior to any study specific procedures;
- Men and women 18 years or older；
- Diagnosed CHD needed to and can be treated with PCI according to the guidelines of ACC/AHA；
- Willingness to participate in the follow-up study for at least 1 year.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nanjing First Hospital Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.